CoChat

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Fibroblast activation protein activated antifibrotic peptide delivery attenuates fibrosis in mouse models of liver fibrosis

Open access
Lee, Jaiwoo, Byun, Junho, Shim, Gayong, Oh, Yu-Kyoung · 2022 · Nature Communications

Abstract

In liver fibrosis, activated hepatic stellate cells are known to overexpress fibroblast activation protein. Here we report a targeted antifibrotic peptide-delivery system in which fibroblast activation protein, which is overexpressed in fibrotic regions of the liver, liberates the antifibrotic peptide melittin by cleaving a fibroblast activation protein-specific site in the peptide. The promelittin peptide is linked to pegylated and maleimide-functionalized liposomes, resulting in promelittin-modified liposomes. The promelittin-modified liposomes were effective in reducing the viability of activated hepatic stellate cells but not that of control cells. In three types of liver fibrosis mouse models, intravenously administered promelittin-modified liposomes significantly reduces fibrotic regions. In addition, in the bile duct ligation mouse model promelittin-modified liposome-treatment increases overall survival. Although this peptide-delivery concept was tested for liver fibrosis, it can potentially be adapted to other fibrotic diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-022-29186-8

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Proposed working mechanism of PRL against liver fibrosis. a Schematic illustration of various liposome formulations. FAP-responsive PRL were synthesized by linking cys-promelittin onto the surface of ML. b In a fibrotic microenvironment, the promelittin moiety on PRL is cleaved by FAP on aHSC. FAP-mediated cleavage of promelittin on PRL releases melittin, which diffuses to nearby aHSC, creating pores in their cell membranes. The resulting reduction in the number of aHSC in fibrotic tissues leads to decreased production of collagens and regression of fibrosis. PL plain PEGylated liposomes; ML maleimide-activated PEGylated liposomes; SCL scrambled cys-promelittin peptide-tagged liposomes; FQL promelittin-mimicking fluorescence-quenched peptide-tagged liposomes; PRL promelittin-modified liposomes; FAP fibroblast activation protein; EDANS, 5-[(2-aminoethyl) amino]naphthalene-1-sulfonic acid; HSC hepatic stellate cell.
Fig. 1 Proposed working mechanism of PRL against liver fibrosis. a Schematic illustration of various liposome formulations. FAP-responsive PRL were synthesized by linking cys-promelittin onto the surface of ML. b In a fibrotic microenvironment, the promelittin moiety on PRL is cleaved by FAP on aHSC. FAP-mediated cleavage of promelittin on PRL releases melittin, which diffuses to nearby aHSC, creating pores in their cell membranes. The resulting reduction in the number of aHSC in fibrotic tissues leads to decreased production of collagens and regression of fibrosis. PL plain PEGylated liposomes; ML maleimide-activated PEGylated liposomes; SCL scrambled cys-promelittin peptide-tagged liposomes; FQL promelittin-mimicking fluorescence-quenched peptide-tagged liposomes; PRL promelittin-modified liposomes; FAP fibroblast activation protein; EDANS, 5-[(2-aminoethyl) amino]naphthalene-1-sulfonic acid; HSC hepatic stellate cell.CC BY · PubMed Central
Fig. 2 FAP-specific cleavage of promelittin peptide on PRL. a Transmission electron microscopy (TEM) imaging. TEM images of liposomes, obtained using a Talos L120C TEM system operating at 120 kV. Scale bar: 100 nm. b Size measurements. Liposomes size was measured using dynamic light scattering (n = 5 independent samples per group). Significant differences were assessed using a one-way ANOVA with Tukey test (n.s.: P > 0.05). Results are presented as mean ± S.D. c Zeta potential measurements. Zeta potential of liposomes was measured by electrophoretic light scattering (n = 5 independent samples per group). Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test PPRL–PL < 0.0001, PPRL–ML < 0.0001, PPRL-SCL > 0.05). Results are presented as mean ± S.D. d Peptide-to-phospholipid ratios were estimated using fluorescamine and phosphate assays (n = 5 independent samples per group). Significant differences were assessed using a one-way ANOVA with Tukey test (n.s.: P > 0.05). Results are presented as mean ± S.D. e, f The hemolytic activity of PRL against mouse red blood cells (RBCs) was evaluated using hemolysis assays (n = 5 independent samples per group). Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test (−) FAP; n.s.: P > 0.05, (+) FAP: PPRL-untreated < 0.0001, PPRL-PL < 0.0001, PPRL-ML < 0.0001, PPRL-SCL < 0.0001). Results are presented as mean ± S.D. g Release kinetics of melittin from PRL. PRL was incubated with or without FAP for various periods. The release of melittin at each point was measured by fluorescamine assay (n = 5 independent samples per group). Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test P(+)FAP - (−)FAP < 0.0001). Results are presented as mean ± S.D. h Design of promelittin-mimicking fluorescence-quenched peptide-tagged liposomes (FQL). A fluorescent FRET (fluorescence resonance energy transfer) moiety was attached to the promelittin-mimicking peptide containing a FAP-dependent cleavage site, and the FAP-specific activity of the peptide was determined by assessing FAP-responsive fluorescence. i Fluorescence emission spectra of FQL observed after FAP or MMP treatment. j Mean fluorescent intensity of FQL at an emission wavelength of 490 nm (n = 5 independent samples per group). Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test PFAP+FQL - FQL < 0.0001, PFAP+FQL - MMP+FQL < 0.0001). Results are presented as mean ± S.D. k Release kinetics of DABCYL-modified peptides from FQL. FQL was incubated in the absence or presence of FAP, or in the presence of MMP. The release of DABCYL-modified peptides was evaluated via spectrofluorometry (n = 5 independent samples per group). Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test P(+)FAP - (+)MMP <0.0001, P(+)FAP - (−)FAP < 0.0001). Results are presented as mean ± S.D. PL plain PEGylated liposomes; ML maleimide-activated PEGylated liposomes; SCL scrambled cys-promelittin peptide-tagged liposomes; FQL promelittin-mimicking fluorescence-quenched peptide-tagged liposomes; PRL promelittin-modified liposomes; h hour; DABCYL 4-((4-(dimethylamino) phenyl)azo)benzoic acid; MMP matrix metalloproteinase. Source data are provided as a Source Data file.
Fig. 2 FAP-specific cleavage of promelittin peptide on PRL. a Transmission electron microscopy (TEM) imaging. TEM images of liposomes, obtained using a Talos L120C TEM system operating at 120 kV. Scale bar: 100 nm. b Size measurements. Liposomes size was measured using dynamic light scattering (n = 5 independent samples per group). Significant differences were assessed using a one-way ANOVA with Tukey test (n.s.: P > 0.05). Results are presented as mean ± S.D. c Zeta potential measurements. Zeta potential of liposomes was measured by electrophoretic light scattering (n = 5 independent samples per group). Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test PPRL–PL < 0.0001, PPRL–ML < 0.0001, PPRL-SCL > 0.05). Results are presented as mean ± S.D. d Peptide-to-phospholipid ratios were estimated using fluorescamine and phosphate assays (n = 5 independent samples per group). Significant differences were assessed using a one-way ANOVA with Tukey test (n.s.: P > 0.05). Results are presented as mean ± S.D. e, f The hemolytic activity of PRL against mouse red blood cells (RBCs) was evaluated using hemolysis assays (n = 5 independent samples per group). Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test (−) FAP; n.s.: P > 0.05, (+) FAP: PPRL-untreated < 0.0001, PPRL-PL < 0.0001, PPRL-ML < 0.0001, PPRL-SCL < 0.0001). Results are presented as mean ± S.D. g Release kinetics of melittin from PRL. PRL was incubated with or without FAP for various periods. The release of melittin at each point was measured by fluorescamine assay (n = 5 independent samples per group). Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test P(+)FAP - (−)FAP < 0.0001). Results are presented as mean ± S.D. h Design of promelittin-mimicking fluorescence-quenched peptide-tagged liposomes (FQL). A fluorescent FRET (fluorescence resonance energy transfer) moiety was attached to the promelittin-mimicking peptide containing a FAP-dependent cleavage site, and the FAP-specific activity of the peptide was determined by assessing FAP-responsive fluorescence. i Fluorescence emission spectra of FQL observed after FAP or MMP treatment. j Mean fluorescent intensity of FQL at an emission wavelength of 490 nm (n = 5 independent samples per group). Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test PFAP+FQL - FQL < 0.0001, PFAP+FQL - MMP+FQL < 0.0001). Results are presented as mean ± S.D. k Release kinetics of DABCYL-modified peptides from FQL. FQL was incubated in the absence or presence of FAP, or in the presence of MMP. The release of DABCYL-modified peptides was evaluated via spectrofluorometry (n = 5 independent samples per group). Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test P(+)FAP - (+)MMP <0.0001, P(+)FAP - (−)FAP < 0.0001). Results are presented as mean ± S.D. PL plain PEGylated liposomes; ML maleimide-activated PEGylated liposomes; SCL scrambled cys-promelittin peptide-tagged liposomes; FQL promelittin-mimicking fluorescence-quenched peptide-tagged liposomes; PRL promelittin-modified liposomes; h hour; DABCYL 4-((4-(dimethylamino) phenyl)azo)benzoic acid; MMP matrix metalloproteinase. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 3 Viability of normal and hepatic stellate cells after treatment with various liposome formulations. a LX-2 cells, Chang cells, and siSCR or siFAP-treated LX-2 cells were stained with rabbit anti-FAP primary antibody and FITC-conjugated anti-rabbit secondary antibody. Fluorescence-positive cells were determined by flow cytometry (n = 5 biologically independent samples per group). b FAP positive cell population was analyzed between LX-2 cells, Chang cells, and siSCR or siFAP-treated LX-2. Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test PLX-2 - Chang < 0.0001, PLX-2 - siFAP LX-2 < 0.0001, PLX-2 - siSCR LX-2 < 0.0001). Results are presented as mean ± S.D. c The efficiency of the siFAP in LX-2 cells was evaluated compare to siSCR. Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test PsiFAP - siSCR < 0.0001). Results are presented as mean ± S.D. d Representative confocal images evaluating the efficiency of siFAP in LX-2 cells. Red color indicates FAP expression. e The fluorescence emission intensity of FQL was measured at a wavelength of 490 nm after incubation with LX-2 cells, Chang cells, or siFAP-treated LX-2 cells (n = 5 biologically independent samples per group). Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test PLX-2 - Chang < 0.0001, PLX-2 - siFAP LX-2 < 0.0001). Results are presented as mean ± S.D. f MTT assays were used to determine cell viability of following treatment with various liposome formulations (n = 5 biologically independent samples per group). Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test PPRL treated LX-2 - others < 0.0001). Results are presented as mean ± S.D. g–i Fluorescence microscopy assessment of live (green)/dead (red) Chang cells (g), siFAP-treated LX-2 cells (h), and LX-2 cells (i). Scale bar: 50 μm. PL plain PEGylated liposomes; ML maleimide-activated PEGylated liposomes; SCL scrambled cys-promelittin peptide-tagged liposomes; PRL promelittin-modified liposomes. Source data are provided as a Source Data file.
Fig. 3 Viability of normal and hepatic stellate cells after treatment with various liposome formulations. a LX-2 cells, Chang cells, and siSCR or siFAP-treated LX-2 cells were stained with rabbit anti-FAP primary antibody and FITC-conjugated anti-rabbit secondary antibody. Fluorescence-positive cells were determined by flow cytometry (n = 5 biologically independent samples per group). b FAP positive cell population was analyzed between LX-2 cells, Chang cells, and siSCR or siFAP-treated LX-2. Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test PLX-2 - Chang < 0.0001, PLX-2 - siFAP LX-2 < 0.0001, PLX-2 - siSCR LX-2 < 0.0001). Results are presented as mean ± S.D. c The efficiency of the siFAP in LX-2 cells was evaluated compare to siSCR. Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test PsiFAP - siSCR < 0.0001). Results are presented as mean ± S.D. d Representative confocal images evaluating the efficiency of siFAP in LX-2 cells. Red color indicates FAP expression. e The fluorescence emission intensity of FQL was measured at a wavelength of 490 nm after incubation with LX-2 cells, Chang cells, or siFAP-treated LX-2 cells (n = 5 biologically independent samples per group). Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test PLX-2 - Chang < 0.0001, PLX-2 - siFAP LX-2 < 0.0001). Results are presented as mean ± S.D. f MTT assays were used to determine cell viability of following treatment with various liposome formulations (n = 5 biologically independent samples per group). Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test PPRL treated LX-2 - others < 0.0001). Results are presented as mean ± S.D. g–i Fluorescence microscopy assessment of live (green)/dead (red) Chang cells (g), siFAP-treated LX-2 cells (h), and LX-2 cells (i). Scale bar: 50 μm. PL plain PEGylated liposomes; ML maleimide-activated PEGylated liposomes; SCL scrambled cys-promelittin peptide-tagged liposomes; PRL promelittin-modified liposomes. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 4 FAP-mediated cleavage of liposomal promelittin in BDL induced fibrosis mice. a Experimental scheme for induction of liver fibrosis using the BDL method (n = 5 biologically independent mice per group). b, c FAP expression level in HSC from normal mice or BDL mice was analyzed by flow cytometry. (n = 5 biologically independent samples per group). Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test PBDL - Normal < 0.0001). Results are presented as mean ± S.D. d Immunohistochemical staining for FAP in liver tissues from normal and BDL mice (n = 5 biologically independent samples per group). Scale bar: 50 μm. e One hour after mice were intravenously injected with FQL, the fluorescence intensities of vital organs (liver, heart, lung, spleen, kidney) from normal and BDL mice were monitored using an IVIS Spectrum instrument equipped with excitation wavelength at 335 nm and emission wavelength at 490 nm. Living image (v4.5.2., PerkinElmer) was used to analyze fluorescent images of mice. The color bar indicates fluorescence intensity (n = 5 biologically independent samples per group). f Fluorescence intensity of each organ was calculated between normal and BDL mice. Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test n.s.: P > 0.05, Liver: PBDL + FQL - Normal < 0.0001, PBDL+FQL - Normal+FQL < 0.0001, PBDL+FQL - BDL < 0.0001). Results are presented as mean ± S.D. BDL bile duct ligation; αSMA alpha-smooth muscle actin; HSC hepatic stellate cell; PL plain PEGylated liposomes; ML maleimide-activated PEGylated liposomes; SCL scrambled cys-promelittin peptide-tagged liposomes; FQL promelittin-mimicking fluorescence-quenched peptide-tagged liposomes; PRL promelittin-modified liposomes. Source data are provided as a Source Data file.
Fig. 4 FAP-mediated cleavage of liposomal promelittin in BDL induced fibrosis mice. a Experimental scheme for induction of liver fibrosis using the BDL method (n = 5 biologically independent mice per group). b, c FAP expression level in HSC from normal mice or BDL mice was analyzed by flow cytometry. (n = 5 biologically independent samples per group). Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test PBDL - Normal < 0.0001). Results are presented as mean ± S.D. d Immunohistochemical staining for FAP in liver tissues from normal and BDL mice (n = 5 biologically independent samples per group). Scale bar: 50 μm. e One hour after mice were intravenously injected with FQL, the fluorescence intensities of vital organs (liver, heart, lung, spleen, kidney) from normal and BDL mice were monitored using an IVIS Spectrum instrument equipped with excitation wavelength at 335 nm and emission wavelength at 490 nm. Living image (v4.5.2., PerkinElmer) was used to analyze fluorescent images of mice. The color bar indicates fluorescence intensity (n = 5 biologically independent samples per group). f Fluorescence intensity of each organ was calculated between normal and BDL mice. Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test n.s.: P > 0.05, Liver: PBDL + FQL - Normal < 0.0001, PBDL+FQL - Normal+FQL < 0.0001, PBDL+FQL - BDL < 0.0001). Results are presented as mean ± S.D. BDL bile duct ligation; αSMA alpha-smooth muscle actin; HSC hepatic stellate cell; PL plain PEGylated liposomes; ML maleimide-activated PEGylated liposomes; SCL scrambled cys-promelittin peptide-tagged liposomes; FQL promelittin-mimicking fluorescence-quenched peptide-tagged liposomes; PRL promelittin-modified liposomes. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 5 In vivo antifibrotic effects of various liposome preparations in the BDL induced lifer fibrosis model. a On days 1 and 3 after BDL surgery, mice were intravenously administered 1 mg/kg PL, ML, SCL, or PRL. On day 4, liver tissues were extracted and further analyzed. b Top panel shows representative Masson’s trichrome-staining in BDL induced fibrotic liver. Lower panel shows pseudocolored images by InForm 2.2.1 analysis, distinguishing fibrotic regions (blue) from normal tissue (red). Bottom panel shows representative H&E staining in BDL-induced fibrotic liver treated with various liposomes. (n = 5 biologically independent mice per group). Scale bar: 50 μm. c Quantification of connective tissue area, calculated from whole images of stained liver, as calculated from five randomly selected fields per sample (n = 5 biologically independent mice per group). Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test PPRL–untreated < 0.0001, PPRL–PL < 0.0001, PPRL–ML < 0.0001, PPRL–SCL < 0.0001). In box plots, boxes show the 25th–75th percentile with the median, and whiskers show the minimum–maximum. d The severity of liver fibrosis for each group, assessed using the METAVIR scoring (n = 5 biologically independent mice per group). Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test PPRL–untreated = 0.0002, PPRL–PL = 0.0004, PPRL–ML = 0.0004, PPRL–SCL = 0.0013). Results are presented as mean ± S.D. e Collagen content of fibrotic liver samples, measured using hydroxyproline assays (n = 5 biologically independent mice per group). Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test PPRL–untreated < 0.0001, PPRL–PL < 0.0001, PPRL–ML < 0.0001, PPRL–SCL < 0.0001). Results are presented as mean ± S.D. f Survival rates of BDL mice after treatment with various liposome formulations (n = 10 biologically independent mice per group). g BDL-induced mice were treated with various liposomes. One day after the last dose, liver tissues were frozen-sectioned and stained with antibodies against F4/80 (macrophage), CD26 (hepatocyte), CD31 (endothelial cell), Ck7 (cholangiocyte), and αSMA (aHSC). h Populations of cells were analyzed using a VECTRA tissue analyzer and the InForm 2.2.1 image analysis software (n = 5 biologically independent mice per group). Scale bar: 50 µm. Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test n.s.: P > 0.05, Ck7: PPRL–untreated = 0.0002, PPRL–PL < 0.0001, PPRL–ML = 0.0056, PPRL–SCL < 0.0007, αSMA: PPRL–untreated < 0.0001, PPRL–PL < 0.0001, PPRL–ML < 0.0001, PPRL–SCL < 0.0001). In box plots, boxes show the 25th–75th percentile with the median, and whiskers show the minimum–maximum. On day 4 after BDL surgery, blood was collected for serum analysis of ALT (i), AST (j), total bilirubin (k), and bile acid (l) (n = 5 biologically independent samples per group). Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test ALT: PPRL–untreated < 0.0001, PPRL–PL < 0.0001, PPRL–ML < 0.0001, PPRL–SCL < 0.0001, AST: PPRL–untreated < 0.0001, PPRL–PL < 0.0001, PPRL–ML < 0.0001, PPRL–SCL < 0.0001, Total bilirubin: pPRL–untreated < 0.0001, PPRL–PL < 0.0001, PPRL–ML < 0.0001, PPRL–SCL < 0.0001, Bile acid: PPRL–untreated < 0.0001, PPRL–PL < 0.0001, PPRL–ML < 0.0001, PPRL–SCL < 0.0001). Results are presented as mean ± S.D. m Liver tissues were stained with TUNEL, followed by immune fluorescence staining with antibodies against αSMA, F4/80, or CD26, and final counter staining with DAPI. Representative images of each group (n = 5 biologically independent mice per group) are shown. White arrows show TUNEL-positive spots. Scale bar: 50 µm. n Analysis of TUNEL-positive cells in five randomly selected fields per sample as calculated from five randomly selected fields per sample (n = 5 biologically independent mice per group). Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test PαSMA+ - F4/80+ < 0.0001, PαSMA+ - CD26+ < 0.0001, PαSMA+ - Ck7+ < 0.0001). In box plots, boxes show the 25th–75th percentile with the median, and whiskers show the minimum–maximum. BDL bile duct ligation; PL plain PEGylated liposomes; ML maleimide-activated PEGylated liposomes; SCL scrambled cys-promelittin peptide-tagged liposomes; PRL promelittin-modified liposomes; CD26 cluster of differentiation 26; CD31 cluster of differentiation 31; Ck7 cytokeratin7; αSMA alpha-smooth muscle actin; ALT alanine transaminase; AST aspartate transaminase; TUNEL terminal deoxynucleotidyl transferase dUTP nick end labeling assay. Source data are provided as a Source Data file.
Fig. 5 In vivo antifibrotic effects of various liposome preparations in the BDL induced lifer fibrosis model. a On days 1 and 3 after BDL surgery, mice were intravenously administered 1 mg/kg PL, ML, SCL, or PRL. On day 4, liver tissues were extracted and further analyzed. b Top panel shows representative Masson’s trichrome-staining in BDL induced fibrotic liver. Lower panel shows pseudocolored images by InForm 2.2.1 analysis, distinguishing fibrotic regions (blue) from normal tissue (red). Bottom panel shows representative H&E staining in BDL-induced fibrotic liver treated with various liposomes. (n = 5 biologically independent mice per group). Scale bar: 50 μm. c Quantification of connective tissue area, calculated from whole images of stained liver, as calculated from five randomly selected fields per sample (n = 5 biologically independent mice per group). Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test PPRL–untreated < 0.0001, PPRL–PL < 0.0001, PPRL–ML < 0.0001, PPRL–SCL < 0.0001). In box plots, boxes show the 25th–75th percentile with the median, and whiskers show the minimum–maximum. d The severity of liver fibrosis for each group, assessed using the METAVIR scoring (n = 5 biologically independent mice per group). Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test PPRL–untreated = 0.0002, PPRL–PL = 0.0004, PPRL–ML = 0.0004, PPRL–SCL = 0.0013). Results are presented as mean ± S.D. e Collagen content of fibrotic liver samples, measured using hydroxyproline assays (n = 5 biologically independent mice per group). Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test PPRL–untreated < 0.0001, PPRL–PL < 0.0001, PPRL–ML < 0.0001, PPRL–SCL < 0.0001). Results are presented as mean ± S.D. f Survival rates of BDL mice after treatment with various liposome formulations (n = 10 biologically independent mice per group). g BDL-induced mice were treated with various liposomes. One day after the last dose, liver tissues were frozen-sectioned and stained with antibodies against F4/80 (macrophage), CD26 (hepatocyte), CD31 (endothelial cell), Ck7 (cholangiocyte), and αSMA (aHSC). h Populations of cells were analyzed using a VECTRA tissue analyzer and the InForm 2.2.1 image analysis software (n = 5 biologically independent mice per group). Scale bar: 50 µm. Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test n.s.: P > 0.05, Ck7: PPRL–untreated = 0.0002, PPRL–PL < 0.0001, PPRL–ML = 0.0056, PPRL–SCL < 0.0007, αSMA: PPRL–untreated < 0.0001, PPRL–PL < 0.0001, PPRL–ML < 0.0001, PPRL–SCL < 0.0001). In box plots, boxes show the 25th–75th percentile with the median, and whiskers show the minimum–maximum. On day 4 after BDL surgery, blood was collected for serum analysis of ALT (i), AST (j), total bilirubin (k), and bile acid (l) (n = 5 biologically independent samples per group). Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test ALT: PPRL–untreated < 0.0001, PPRL–PL < 0.0001, PPRL–ML < 0.0001, PPRL–SCL < 0.0001, AST: PPRL–untreated < 0.0001, PPRL–PL < 0.0001, PPRL–ML < 0.0001, PPRL–SCL < 0.0001, Total bilirubin: pPRL–untreated < 0.0001, PPRL–PL < 0.0001, PPRL–ML < 0.0001, PPRL–SCL < 0.0001, Bile acid: PPRL–untreated < 0.0001, PPRL–PL < 0.0001, PPRL–ML < 0.0001, PPRL–SCL < 0.0001). Results are presented as mean ± S.D. m Liver tissues were stained with TUNEL, followed by immune fluorescence staining with antibodies against αSMA, F4/80, or CD26, and final counter staining with DAPI. Representative images of each group (n = 5 biologically independent mice per group) are shown. White arrows show TUNEL-positive spots. Scale bar: 50 µm. n Analysis of TUNEL-positive cells in five randomly selected fields per sample as calculated from five randomly selected fields per sample (n = 5 biologically independent mice per group). Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test PαSMA+ - F4/80+ < 0.0001, PαSMA+ - CD26+ < 0.0001, PαSMA+ - Ck7+ < 0.0001). In box plots, boxes show the 25th–75th percentile with the median, and whiskers show the minimum–maximum. BDL bile duct ligation; PL plain PEGylated liposomes; ML maleimide-activated PEGylated liposomes; SCL scrambled cys-promelittin peptide-tagged liposomes; PRL promelittin-modified liposomes; CD26 cluster of differentiation 26; CD31 cluster of differentiation 31; Ck7 cytokeratin7; αSMA alpha-smooth muscle actin; ALT alanine transaminase; AST aspartate transaminase; TUNEL terminal deoxynucleotidyl transferase dUTP nick end labeling assay. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 6 In vivo antifibrotic effects of various liposome preparations in the CCl4-induced liver fibrosis model. a Schematic of the CCl4-induced liver fibrosis model and treatment timelines for the various liposomes. b Immunohistochemical staining for FAP in liver tissues from normal and CCl4-induced liver fibrosis mice (n = 5 biologically independent samples per group). Scale bar: 50 μm. c, d FAP expression levels on HSCs from normal or CCl4-induced fibrotic liver were analyzed by flow cytometry (n = 5 biologically independent mice per group). Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test PCCl4(+) - Normal < 0.0001). Results are presented as mean ± S.D. e, f Representative Sirius red-stained liver images for the evaluation of liver fibrosis, and quantification of the Sirius red-positive area (n = 5 biologically independent mice per group). Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test PPRL–normal < 0.0001, PPRL–untreated < 0.0001, PPRL–PL < 0.0001, PPRL–ML < 0.0001, PPRL–SCL < 0.0001). In box plots, boxes show the 25th–75th percentile with the median, and whiskers show the minimum–maximum. g Upper panel shows representative Masson’s trichrome-stained images of CCl4-induced fibrotic liver. The lower panel displays pseudocolored images by InForm 2.2.1 analysis, distinguishing fibrotic regions (blue) from normal tissue (red) (n = 5 biologically independent mice per group). Scale bar: 50 μm. h Quantification of the connective tissue area under Masson’s trichrome staining, as calculated from five randomly selected fields per sample (n = 5 biologically independent mice per group). Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test PPRL–normal = 0.3374, PPRL–untreated < 0.0001, PPRL–PL < 0.0001, PPRL–ML < 0.0001, PPRL–SCL < 0.0001). In box plots, boxes show the 25th–75th percentile with the median, and whiskers show the minimum–maximum. i The severity of liver fibrosis for each group, assessed using the METAVIR scoring system (n = 5 biologically independent mice per group). Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test PPRL–normal = 0.2537, PPRL–untreated = 0.0073, PPRL–PL = 0.0270, PPRL–ML = 0.0270, PPRL–SCL = 0.0270). Results are presented as mean ± S.D. j Collagen content of fibrotic liver samples, as measured using hydroxyproline assays. Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test PPRL–normal = 0.1882, PPRL–untreated = 0.0002, PPRL–PL = 0.0005, PPRL–ML = 0.0012, PPRL–SCL = 0.0014). Results are presented as mean ± S.D. Blood was collected for serum analysis of AST (k) and ALT (l) (n = 5 biologically independent mice per group), UT: untreated group. Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test AST: PPRL–normal = 0.3160, PPRL–untreated < 0.0001, PPRL–PL < 0.0001, PPRL–ML < 0.0001, PPRL–SCL < 0.0001, ALT: PPRL–normal = 0.9998, PPRL–untreated < 0.0001, PPRL–PL < 0.0001, PPRL–ML < 0.0001, PPRL–SCL < 0.0001). Results are presented as mean ± S.D. m Representative immunofluorescence images of liver tissues stained with various cell markers including F4/80 (macrophage), CD26 (hepatocyte), CD31 (endothelial cell), Ck7 (cholangiocyte), and αSMA (aHSC). n Populations of cells were analyzed using a VECTRA tissue analyzer and the InForm 2.2.1 image analysis software (n = 5 biologically independent mice per group). Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test n.s.: P > 0.05, αSMA: PPRL–untreated < 0.0001, PPRL–PL < 0.0001, PPRL–ML < 0.0001, PPRL–SCL < 0.0001). In box plots, boxes show the 25th–75th percentile with the median, and whiskers show the minimum–maximum. Scale bar: 50 µm. HSC hepatic stellate cell; UT untreated group; PL plain PEGylated liposomes; ML maleimide-activated PEGylated liposomes; SCL scrambled cys-promelittin peptide-tagged liposomes; PRL promelittin-modified liposomes; CD26 cluster of differentiation 26; CD31 cluster of differentiation 31; Ck7 cytokeratin7; αSMA alpha-smooth muscle actin; ALT alanine transaminase; AST aspartate transaminase. Source data are provided as a Source Data file.
Fig. 6 In vivo antifibrotic effects of various liposome preparations in the CCl4-induced liver fibrosis model. a Schematic of the CCl4-induced liver fibrosis model and treatment timelines for the various liposomes. b Immunohistochemical staining for FAP in liver tissues from normal and CCl4-induced liver fibrosis mice (n = 5 biologically independent samples per group). Scale bar: 50 μm. c, d FAP expression levels on HSCs from normal or CCl4-induced fibrotic liver were analyzed by flow cytometry (n = 5 biologically independent mice per group). Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test PCCl4(+) - Normal < 0.0001). Results are presented as mean ± S.D. e, f Representative Sirius red-stained liver images for the evaluation of liver fibrosis, and quantification of the Sirius red-positive area (n = 5 biologically independent mice per group). Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test PPRL–normal < 0.0001, PPRL–untreated < 0.0001, PPRL–PL < 0.0001, PPRL–ML < 0.0001, PPRL–SCL < 0.0001). In box plots, boxes show the 25th–75th percentile with the median, and whiskers show the minimum–maximum. g Upper panel shows representative Masson’s trichrome-stained images of CCl4-induced fibrotic liver. The lower panel displays pseudocolored images by InForm 2.2.1 analysis, distinguishing fibrotic regions (blue) from normal tissue (red) (n = 5 biologically independent mice per group). Scale bar: 50 μm. h Quantification of the connective tissue area under Masson’s trichrome staining, as calculated from five randomly selected fields per sample (n = 5 biologically independent mice per group). Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test PPRL–normal = 0.3374, PPRL–untreated < 0.0001, PPRL–PL < 0.0001, PPRL–ML < 0.0001, PPRL–SCL < 0.0001). In box plots, boxes show the 25th–75th percentile with the median, and whiskers show the minimum–maximum. i The severity of liver fibrosis for each group, assessed using the METAVIR scoring system (n = 5 biologically independent mice per group). Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test PPRL–normal = 0.2537, PPRL–untreated = 0.0073, PPRL–PL = 0.0270, PPRL–ML = 0.0270, PPRL–SCL = 0.0270). Results are presented as mean ± S.D. j Collagen content of fibrotic liver samples, as measured using hydroxyproline assays. Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test PPRL–normal = 0.1882, PPRL–untreated = 0.0002, PPRL–PL = 0.0005, PPRL–ML = 0.0012, PPRL–SCL = 0.0014). Results are presented as mean ± S.D. Blood was collected for serum analysis of AST (k) and ALT (l) (n = 5 biologically independent mice per group), UT: untreated group. Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test AST: PPRL–normal = 0.3160, PPRL–untreated < 0.0001, PPRL–PL < 0.0001, PPRL–ML < 0.0001, PPRL–SCL < 0.0001, ALT: PPRL–normal = 0.9998, PPRL–untreated < 0.0001, PPRL–PL < 0.0001, PPRL–ML < 0.0001, PPRL–SCL < 0.0001). Results are presented as mean ± S.D. m Representative immunofluorescence images of liver tissues stained with various cell markers including F4/80 (macrophage), CD26 (hepatocyte), CD31 (endothelial cell), Ck7 (cholangiocyte), and αSMA (aHSC). n Populations of cells were analyzed using a VECTRA tissue analyzer and the InForm 2.2.1 image analysis software (n = 5 biologically independent mice per group). Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test n.s.: P > 0.05, αSMA: PPRL–untreated < 0.0001, PPRL–PL < 0.0001, PPRL–ML < 0.0001, PPRL–SCL < 0.0001). In box plots, boxes show the 25th–75th percentile with the median, and whiskers show the minimum–maximum. Scale bar: 50 µm. HSC hepatic stellate cell; UT untreated group; PL plain PEGylated liposomes; ML maleimide-activated PEGylated liposomes; SCL scrambled cys-promelittin peptide-tagged liposomes; PRL promelittin-modified liposomes; CD26 cluster of differentiation 26; CD31 cluster of differentiation 31; Ck7 cytokeratin7; αSMA alpha-smooth muscle actin; ALT alanine transaminase; AST aspartate transaminase. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 7 In vivo antifibrotic effects of various liposome preparations in the CDAHFD-induced fibrosis model. a Schematic of the CDAHFD-induced fibrosis model and treatment timelines for the various liposomes. b Representative images of liver sections stained for FAP (green), αSMA (red), and DAPI (blue) (n = 5 biologically independent mice per group). Scale bar: 50 μm. c, d FAP expression levels on HSCs from normal or CDAHFD-induced fibrotic liver were evaluated by flow cytometry (n = 5 biologically independent mice per group). Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test PCDAHFD(+) - Normal < 0.0001). Results are presented as mean ± S.D.. e, f Representative Sirius red-stained liver images for the evaluation of liver fibrosis and quantification of the Sirius red-positive area (n = 5 biologically independent mice per group). Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test PPRL–normal < 0.0001, PPRL–untreated < 0.0001, PPRL–PL < 0.0001, PPRL–ML < 0.0001, PPRL–SCL < 0.0001). In box plots, boxes show the 25th–75th percentile with the median, and whiskers show the minimum–maximum. g Top panel shows representative Masson’s trichrome-staining of liver. Bottom panel displays pseudocolored images by InForm 2.2.1 analysis, distinguishing fibrotic regions (blue) from normal tissue (red) (n = 5 biologically independent mice per group). Scale bar: 50 μm. h Quantification of Masson’s trichrome-stained connective tissue area calculated from five randomly selected fields per sample (n = 5 biologically independent mice per group). Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test PPRL–normal < 0.0001, PPRL–untreated < 0.0001, PPRL–PL < 0.0001, PPRL–ML < 0.0001, PPRL–SCL < 0.0001). In box plots, boxes show the 25th–75th percentile with the median, and whiskers show the minimum–maximum. i Collagen content of fibrotic liver samples, as measured using hydroxyproline assays. Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test PPRL–normal = 0.1877, PPRL–untreated < 0.0001, PPRL–PL < 0.0001, PPRL–ML < 0.0001, PPRL–SCL = 0.0001). Results are presented as mean ± S.D. Blood was collected for serum analysis of AST (j) and ALT (k) (n = 5 biologically independent mice per group). Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test AST: PPRL–normal = 0.7672, PPRL–untreated = 0.0002, PPRL–PL = 0.0002, PPRL–ML = 0.0005, PPRL–SCL = 0.0003, ALT: PPRL–normal = 0.9835, PPRL–untreated < 0.0001, PPRL–PL < 0.0001, PPRL–ML < 0.0001, PPRL–SCL < 0.0001). Results are presented as mean ± S.D. CDAHFD, a choline-deficient, L-amino acid-defined high-fat diet; HSC hepatic stellate cell; UT untreated group. PL plain PEGylated liposomes; ML maleimide-activated PEGylated liposomes; SCL scrambled cys-promelittin peptide-tagged liposomes; PRL promelittin-modified liposomes; CD26 cluster of differentiation 26; CD31 cluster of differentiation 31; Ck7 cytokeratin7; αSMA alpha-smooth muscle actin; ALT alanine transaminase; AST aspartate transaminase. Source data are provided as a Source Data file.
Fig. 7 In vivo antifibrotic effects of various liposome preparations in the CDAHFD-induced fibrosis model. a Schematic of the CDAHFD-induced fibrosis model and treatment timelines for the various liposomes. b Representative images of liver sections stained for FAP (green), αSMA (red), and DAPI (blue) (n = 5 biologically independent mice per group). Scale bar: 50 μm. c, d FAP expression levels on HSCs from normal or CDAHFD-induced fibrotic liver were evaluated by flow cytometry (n = 5 biologically independent mice per group). Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test PCDAHFD(+) - Normal < 0.0001). Results are presented as mean ± S.D.. e, f Representative Sirius red-stained liver images for the evaluation of liver fibrosis and quantification of the Sirius red-positive area (n = 5 biologically independent mice per group). Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test PPRL–normal < 0.0001, PPRL–untreated < 0.0001, PPRL–PL < 0.0001, PPRL–ML < 0.0001, PPRL–SCL < 0.0001). In box plots, boxes show the 25th–75th percentile with the median, and whiskers show the minimum–maximum. g Top panel shows representative Masson’s trichrome-staining of liver. Bottom panel displays pseudocolored images by InForm 2.2.1 analysis, distinguishing fibrotic regions (blue) from normal tissue (red) (n = 5 biologically independent mice per group). Scale bar: 50 μm. h Quantification of Masson’s trichrome-stained connective tissue area calculated from five randomly selected fields per sample (n = 5 biologically independent mice per group). Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test PPRL–normal < 0.0001, PPRL–untreated < 0.0001, PPRL–PL < 0.0001, PPRL–ML < 0.0001, PPRL–SCL < 0.0001). In box plots, boxes show the 25th–75th percentile with the median, and whiskers show the minimum–maximum. i Collagen content of fibrotic liver samples, as measured using hydroxyproline assays. Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test PPRL–normal = 0.1877, PPRL–untreated < 0.0001, PPRL–PL < 0.0001, PPRL–ML < 0.0001, PPRL–SCL = 0.0001). Results are presented as mean ± S.D. Blood was collected for serum analysis of AST (j) and ALT (k) (n = 5 biologically independent mice per group). Significant differences were assessed using a one-way ANOVA with Tukey test (Tukey’s test AST: PPRL–normal = 0.7672, PPRL–untreated = 0.0002, PPRL–PL = 0.0002, PPRL–ML = 0.0005, PPRL–SCL = 0.0003, ALT: PPRL–normal = 0.9835, PPRL–untreated < 0.0001, PPRL–PL < 0.0001, PPRL–ML < 0.0001, PPRL–SCL < 0.0001). Results are presented as mean ± S.D. CDAHFD, a choline-deficient, L-amino acid-defined high-fat diet; HSC hepatic stellate cell; UT untreated group. PL plain PEGylated liposomes; ML maleimide-activated PEGylated liposomes; SCL scrambled cys-promelittin peptide-tagged liposomes; PRL promelittin-modified liposomes; CD26 cluster of differentiation 26; CD31 cluster of differentiation 31; Ck7 cytokeratin7; αSMA alpha-smooth muscle actin; ALT alanine transaminase; AST aspartate transaminase. Source data are provided as a Source Data file.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Cited by

See all 79

Metadata

Authors
Lee, J., Byun, J., Shim, G., & Oh, Y.-K.
Affiliations
  • Seoul National University (KR)
  • Soongsil University (KR)
Corresponding author
Oh, Yu-Kyoung
Venue
Nature Communications
Published
2022-03-21
Volume
13
Issue
1
Pages
1516-1516
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4220755333
Cited by
79
References
42
Citations by year
2026: 14 · 2025: 21 · 2024: 18 · 2023: 20 · 2022: 4
FWCI
9.36
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
liver fibrosis, fibroblast activation protein, melittin, hepatic stellate cells, PEGylated liposomes, bile duct ligation, targeted drug delivery, fibrotic diseases
MeSH terms
Animals, Disease Models, Animal, Fibroblasts, Liposomes, Liver, Liver Cirrhosis, Peptides, Mice, Hepatic Stellate Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fibroblast activation protein activated antifibrotic peptide delivery attenuates fibrosis in mouse models of liver fibrosis. https://app.cochat.ai/papers/10.1038/s41467-022-29186-8
The paper
Lee, J., Byun, J., Shim, G., & Oh, Y.-K. (2022). Fibroblast activation protein activated antifibrotic peptide delivery attenuates fibrosis in mouse models of liver fibrosis. Nature Communications. https://doi.org/10.1038/s41467-022-29186-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.